VEGFA and renal cell carcinoma: Other VEGF TKIs approved for the treatment of advanced RCC include pazopanib, axitinib, and cabozantinib.23-25 These agents served as first-line therapies until 2018, when ICI-based combination regimens became the standard of care for frontline treatment of metastatic RCC, with patients either receiving dual ICI or ICI/TKI therapies at diagnosis.26-29